Companies
Profit warnings surge in third quarter
The number of profit warnings issued by UK-listed companies in the third quarter hit their highest level since 2008, as companies faced higher costs and slumping demand.
Some 86 profit warnings were issued during the three-month period, a 69 per cent year-on-year increase and a 34 per cent jump on the second quarter, according to EY-Parthenon.
More than half (57 per cent) of companies issuing warnings cited higher costs and 23 per cent mentioned labour market problems. Consumer-facing firms have been hit hardest, with 11 retailers issuing warnings during the quarter, alongside nine travel and leisure firms and seven food producers. Higher costs were flagged in 70 per cent of warnings from consumer-facing firms, with 50 per cent also citing declining confidence and changing spending patterns from buyers. MF
Pearson prospers as travel increases
Education specialist Pearson (PSON) is on track to meet full-year profit expectations after a very strong performance from its English language arm, as global mobility continues to climb. The group’s sales rose by 7 per cent in the first nine months of 2022, with
‘English language learning sales’ up by 28 per cent. This was partly offset by a decline in the higher education division, where the American college market has thrown up a number of challenges.
Pearson is also on track to deliver at least £100mn of efficiencies in 2023 “which will accelerate improved margin expectations from 2025 to 2023”. Around half of these savings are expected to benefit its struggling higher education arm. JS
Helical shares rise after trading update
Shares in office developer Helical (HLCL) climbed 5 per cent this morning after a positive trading update for the six months to 21 October. The company said it had signed four new lettings over the period, adding £1.3mn to its rent roll at a 1.2 per cent market premium, and that it had sold around £200mn worth of office assets also at a premium.Chief executive Gerald Kaye said: “We have had a good first half of the financial year with both development and leasing targets being met or exceeded.” The company’s shares remain down almost a third year-to-date. ML
FDA approves AstraZeneca drug combo in liver cancer
Two AstraZeneca (AZN) drugs, Imjudo and Imfinzi, have been approved in the US as a combination therapy to treat adults with the most common form of liver cancer.
The Food and Drug Administration gave the drugs the green light based on positive results from a phase III trial. According to the company, patients treated with the combination experienced a 22 per cent reduction in the risk of death versus those treated with sorafenib – another liver cancer drug.
Results also showed that an estimated 31 per cent of patients treated with Imjudo and Imfinzi were still alive after three years, compared with 20 per cent of patients on sorafenib. Liver cancer is the fastest rising cause of cancer-related deaths in the US, with around 36,000 new diagnoses each year. JJ
Pure Gold calamity worsens
A company we highlighted a few years ago when it added a London listing to its TSX base, Pure Gold (PUR), has almost thrown in the towel after a year of production issues and geological confusion at its re-opened gold mine in Ontario. The company said on Monday morning it had been unable to either reach positive cash flow or raise new cash because of the weakness of its share price, and would stop operations at its underground mine immediately.
Trouble began last year when the content of gold in the ore being mined was lower than expected, and the former chief executive was rolled in January, while the company slashed mine manager roles and looked for other cash savings. Pure Gold was trading over 160p two years ago but fell to 60p 12 months ago and is now at 2p, falling 71 per cent on Monday morning. AH